Geron Corporation to Present at UBS Global Life Sciences Conference
MENLO PARK, Calif., Sept. 24, 2007 – Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 9:30 a.m. EDT on Tuesday, Sept. 25, 2007, at the UBS Global Life Sciences Conference in New York.
The update will include information about Geron’s portfolio of anti–cancer therapies, including its telomerase inhibitor drug (GRN163L) and its telomerase therapeutic vaccine (GRNVAC1). The presentation will also include a review of the company’s human embryonic stem cell (hESC) development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1) and diabetes (GRNIC1).
The audio only webcast will be available at the following website address: http://www.ibb.ubs.com. To access the webcast, click the Conferences icon in the center right of the page and follow the link for Webcast located next to the 2007 Global Life Sciences Conference heading. The replay will be available 24 hours after the live presentation and will be archived for 30 days.
Geron is developing first–in–class biopharmaceuticals for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti–cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell–based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.
CONTACTS:
Media: David Schull, Russo Partners, LLC, 858–717–2310, david.schull@russopartnersllc.com
Investors: Matthew Haines, Russo Partners, LLC, 212–845–4235, matt.haines@russopartnersllc.com
At Geron: David L. Greenwood, Chief Financial Officer, 650–473–7765, info@geron.com
